This Podcast Will Kill You

From the Vault - Hepatitis B: Hepatiti, Take 2 (Ep 89)

December 23, 2025

Key Takeaways Copied to clipboard!

  • Hepatitis B virus (HBV) is a bizarre, partially double-stranded DNA virus that uniquely utilizes reverse transcriptase for replication, similar to RNA viruses like HIV. 
  • Vertical transmission of Hepatitis B from mother to child occurs overwhelmingly during childbirth, not transplacentally, and results in a chronic infection risk exceeding 90% in untreated infants. 
  • Chronic HBV infection progresses through dynamic phases (immune tolerance, immune active, inactive), and the risk of progression to severe outcomes like liver cancer (15-40%) is significantly worse than that of chronic Hepatitis C. 
  • The discovery of the Hepatitis B virus (initially named Australia antigen) by Baruch Blumberg and Harvey Alter was serendipitous, occurring while they were searching for blood plasma protein polymorphisms, illustrating that scientific progress is often not linear. 
  • The identification of the Hepatitis B virus led to the development of testing, which, while crucial for blood safety (with screening beginning in the early 1970s), also resulted in significant, often overlooked, discrimination and ostracization of infected individuals. 
  • Despite having a highly effective vaccine since 1986, the global burden of Hepatitis B remains staggering, with nearly 300 million chronically infected people, largely due to poor delivery infrastructure, especially concerning timely birth vaccination and treatment of pregnant carriers. 

Segments

Dr. Wang’s Personal Hepatitis B Journey
Copied to clipboard!
(00:02:09)
  • Key Takeaway: Dr. Su Wang was diagnosed with Hepatitis B in college after attempting to donate blood, leading to personal experiences with stigma and the realization of the virus’s impact beyond clinical markers.
  • Summary: Dr. Wang learned of her Hepatitis B diagnosis in college after donating blood, a diagnosis her sister revealed their mother also carried. She initially minimized the condition until medical school screenings highlighted the stigma and discrimination faced by carriers. Her personal journey emphasized the importance of considering quality of life outcomes, not just biochemical tests, for patients living with HBV.
Shifting Focus to Patient Experience
Copied to clipboard!
(00:08:34)
  • Key Takeaway: Physicians often underestimate the profound impact of personal experience, which is crucial for improving quality of life for those living with chronic diseases like Hepatitis B.
  • Summary: Dr. Wang realized the power of personal experience when engaging with the World Hepatitis Alliance, which is led by patients. She learned that medical outcomes (morbidity, mortality) fail to measure the burden of disease on a patient’s quality of life. True progress in disease alleviation requires collaboration between the medical community and people living with the disease, moving beyond biochemical silos.
Introduction to Hepatitis B Virology
Copied to clipboard!
(00:11:43)
  • Key Takeaway: Hepatitis B is a partially double-stranded DNA virus belonging to the hepadinoviridae family, which is unusual because it uses reverse transcriptase for replication.
  • Summary: This episode of This Podcast Will Kill You, titled “From the Vault - Hepatitis B: Hepatiti, Take 2,” focuses on HBV, the second hepatitis virus covered. HBV is classified as a partially double-stranded DNA virus, a structure that is considered very bizarre in virology. Furthermore, it employs reverse transcriptase to replicate its genome, a mechanism typically associated with RNA viruses like HIV.
HBV Transmission and Infectivity
Copied to clipboard!
(00:22:14)
  • Key Takeaway: Hepatitis B is significantly more infectious than HIV (50 to 100 times more infectious) and is transmitted via blood, sexual contact, and vertically during birth.
  • Summary: HBV transmission routes are similar to Hepatitis C but include much easier sexual transmission due to its high infectivity. According to the WHO, HBV is 50 to 100 times more infectious than HIV, and the virus can persist in the environment for at least several days. Vertical transmission risk is extremely high, with 40% to 90% of babies born to chronically infected mothers becoming infected without treatment.
Chronic Infection Risk by Age
Copied to clipboard!
(00:31:24)
  • Key Takeaway: The likelihood of developing chronic Hepatitis B infection is inversely related to the age of exposure, with infants facing over a 90% risk compared to only 2-5% for adults.
  • Summary: For neonates infected vertically, the chance of establishing a chronic infection is over 90%, leading to a high risk of fibrosis and liver cancer. Children infected between ages one and five have a chronic infection risk around 30%. In contrast, adults infected with HBV only face a 2% to 5% risk of developing a chronic infection.
Phases of Chronic HBV Infection
Copied to clipboard!
(00:35:39)
  • Key Takeaway: Chronic HBV infection progresses through distinct phases—immune tolerance, immune active, and inactive—with the immune active phase causing inflammation, fibrosis, and cancer risk.
  • Summary: Chronic HBV infection, defined by antigen persistence for over six months, is dynamic. Infants often enter a long immune tolerance phase where the virus integrates into the genome without much damage. The immune active (or clearance) phase involves the body mounting an immune response, causing inflammation that leads to fibrosis, cirrhosis, and hepatocellular carcinoma.
HBV Evolutionary Origins
Copied to clipboard!
(00:48:12)
  • Key Takeaway: Recent ancient DNA analysis suggests the most recent common ancestor of the Hepatitis B virus originated in Eurasia around 12,000 to 16,000 years ago, predating the Neolithic Revolution.
  • Summary: The evolutionary history of HBV is complex, belonging to the ancient hepadinoviridae family which infected animals millions of years ago. Analysis of viral DNA in ancient skeletal remains suggests the human HBV ancestor emerged more recently in Eurasia. The virus spread globally before large settled populations formed, but diversity increased significantly after the Neolithic Revolution due to increased transmission opportunities.
Early Recognition and Differentiation
Copied to clipboard!
(00:56:26)
  • Key Takeaway: Jaundice has been recognized in ancient texts, but the critical differentiation between blood-borne hepatitis (later B) and food/waterborne hepatitis (later A) was formalized in the early 1940s.
  • Summary: Outbreaks of jaundice, sometimes called ‘campaign jaundice,’ were noted in historical texts, but distinguishing the cause was difficult due to other hepatitis viruses. A major turning point occurred after WWII when 50,000 US Army personnel developed hepatitis following yellow fever vaccination containing human serum. Dr. F.O. McCallum hypothesized two distinct hepatitides (A and B) based on transmission routes, leading to the recognition of blood-borne infection.
Unethical Willowbrook Studies Mentioned
Copied to clipboard!
(01:06:18)
  • Key Takeaway: The unethical Willowbrook State School hepatitis studies, which involved intentionally infecting children, led to major reforms in medical ethics and consent regulations, although they also tested a prototype HBV vaccine.
  • Summary: The Willowbrook studies, sometimes called the pediatric Tuskegee, involved intentionally infecting children with hepatitis to study the disease and test gamma globulin and a prototype HBV vaccine. The resulting public outrage established stricter regulations for including children in clinical trials and revamped standards for obtaining medical consent. While primarily focused on Hepatitis A, HBV was also part of the research conducted by Dr. Saul Krugman.
Willebrook Legacy and Ethics
Copied to clipboard!
(01:08:59)
  • Key Takeaway: The outrage from the Willebrook hepatitis studies resulted in stricter regulations for child clinical trials and medical consent.
  • Summary: The legacy of the Willebrook hepatitis studies includes the implementation of very strict regulations concerning the inclusion of children in clinical trials and a major revamp of medical consent standards. Further reading on the ethics of these studies, including a 1986 paper by Krugman defending his research, is available via the podcast’s website. The hosts note that they did not fully cover the complex ethical history of these studies in this segment.
Accidental Discovery of HBV
Copied to clipboard!
(01:09:56)
  • Key Takeaway: Hepatitis B virus was discovered by researchers not actively looking for it, highlighting the non-linear nature of scientific breakthroughs.
  • Summary: By the 1960s, the Hepatitis B virus remained unidentified despite dedicated research efforts. Its eventual discovery was made by a team, led by Dr. Baruch Blumberg, who were investigating genetic polymorphisms associated with disease susceptibility, not viruses. This accidental finding underscores that science often proceeds by stumbling upon unexpected discoveries rather than following a strictly orderly path.
Blumberg’s Search for Polymorphisms
Copied to clipboard!
(01:11:38)
  • Key Takeaway: Dr. Blumberg initially sought novel blood plasma protein polymorphisms linked to disease susceptibility using techniques like agar gel diffusion.
  • Summary: Dr. Blumberg focused on how genetics interacts with environment and behavior to cause disease, specifically looking for new blood plasma protein polymorphisms, not viruses. He collected global blood samples and used antibodies generated from transfused patients to identify new antigens, such as the AG protein, which was a serum lipoprotein. This early technique, agar gel diffusion, was rudimentary but proved capable of identifying new serum proteins.
Discovery of Australia Antigen
Copied to clipboard!
(01:15:27)
  • Key Takeaway: Harvey Alter and Blumberg identified the ‘Australia antigen’ in blood serum, which was later confirmed to be the Hepatitis B virus.
  • Summary: Harvey Alter, recognized for his role in Hepatitis C research and a 2020 Nobel laureate, collaborated with Blumberg to find another polymorphism. They discovered the ‘Australia antigen’ in the blood of an Australian First Nations person, initially believing it to be a human protein. Geographic prevalence studies and observations of transmission via blood transfusions led researchers to suspect it was an infectious agent, eventually linking it to Hepatitis B.
HBV Identification and Setbacks
Copied to clipboard!
(01:18:50)
  • Key Takeaway: The initial paper identifying the Hepatitis B virus was rejected by a reviewer due to insufficient evidence and the researchers’ lack of prior hepatitis expertise.
  • Summary: Despite strong evidence, Blumberg’s initial paper linking the Australia antigen to the virus was rejected, partly because the field was saturated with false claims about identifying the virus. Furthermore, Blumberg’s team lacked formal training in virology or epidemiology, leading to skepticism from established hepatitis researchers. A paper confirming the finding was eventually published in 1967, a critical time when post-transfusion hepatitis rates reached 30%.
Vaccine Development and Stigma
Copied to clipboard!
(01:21:19)
  • Key Takeaway: Identification of the HBV allowed for blood screening and vaccine development, but also triggered widespread discrimination against carriers.
  • Summary: The discovery enabled testing of blood products and the eventual development of a vaccine, with the first version appearing in 1969 and the recombinant yeast-based vaccine licensed in 1981. However, testing also led to severe discrimination, including job loss and denial of healthcare for those testing positive. Although many discriminatory regulations have been overturned, the stigma associated with Hepatitis B persists.
Nobel Prize and Research Legacy
Copied to clipboard!
(01:25:31)
  • Key Takeaway: Dr. Baruch Blumberg received the 1976 Nobel Prize for identifying the Hepatitis B virus, while Harvey Alter received his in 2020 for Hepatitis C work.
  • Summary: Blumberg was awarded the 1976 Nobel Prize in Physiology or Medicine for his work on identifying the Hepatitis B virus, sharing it with Carlton Gajasek. Research since the discovery has focused on transmission, genotypes, cancer potential, and improved vaccines. Despite these advancements, the virus remains highly prevalent globally, continuing to impose a massive physical, economic, and emotional burden.
Current Global Hepatitis Statistics
Copied to clipboard!
(01:27:39)
  • Key Takeaway: Approximately 300 million people globally live with chronic Hepatitis B, causing about 820,000 deaths annually, with the highest burden in the Western Pacific and African regions.
  • Summary: Globally, nearly 4% of the population lives with chronic Hepatitis B infection, with 1.5 million new infections occurring yearly. Viral hepatitis caused 1.34 million deaths in 2015, with 66% of those chronic deaths attributed to Hepatitis B, equating to 820,000 annual deaths from HBV alone. The prevalence is highly unequal, being much higher in the Western Pacific and African WHO regions compared to North America or Europe.
Gaps in Testing and Prevention
Copied to clipboard!
(01:31:12)
  • Key Takeaway: Only about 10% of people living with chronic Hepatitis B know their status, and only 1% of pregnant people receive necessary testing and treatment to prevent mother-to-child transmission.
  • Summary: A critical failure point is that only about 10.5% of chronically infected individuals are aware of their status, and only 22% of those diagnosed are on treatment. Prevention efforts are severely hampered by low rates of intervention for newborns; only 46% of infants globally receive a timely birth vaccination within the critical 12 to 24-hour window. Furthermore, only about 1% of pregnant people receive the testing and treatment necessary to significantly reduce transmission risk to their babies.
Future Focus and Bonus Episode
Copied to clipboard!
(01:35:01)
  • Key Takeaway: The podcast will release a bonus episode focusing specifically on the substantial stigma and discrimination faced by people living with Hepatitis B.
  • Summary: The hosts acknowledge that the massive global problem of Hepatitis B still involves substantial stigma and discrimination that was not fully covered in the main episode. A bonus episode featuring Dr. Sherry Cohen of the Hepatitis B Foundation will delve deeper into the drivers of this stigma and discrimination. This bonus episode is scheduled for release on Tuesday, February 1st.